You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
|
|---|---|
| Published in |
BMC Nephrology, July 2017
|
| DOI | 10.1186/s12882-017-0644-0 |
| Pubmed ID | |
| Authors |
Yuki Awanami, Makoto Fukuda, Yasunori Nonaka, Tsuyoshi Takashima, Keiichiro Matsumoto, Masatora Yamasaki, Motoaki Miyazono, Yuji Ikeda |
| Abstract |
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with refractory nephrotic syndrome. A 61-year-old woman was diagnosed with minimal change-type nephrotic syndrome in October 2012. She received prednisolone (PSL) and cyclosporin A (CyA), but she experienced several cycles of relapse and remission and was hospitalized in May 2016 due to relapse. However, in spite of steroid pulse therapy and adrenocorticotropic hormone (ACTH) administration, her urinary protein level did not improve. We started her on evolocumab with the expectation of equivalent LDL-lowering effects as seen with LDL apheresis. After that, the LDL cholesterol level and UP/UC were concomitantly decreased, and the serum albumin was increased. This was maintained even when we reduced the PSL dose. This suggests that evolocumab clinically improves the nephrotic condition. No other report has described the use of evolocumab for nephrotic syndrome (NS) or its effect on similar nephrotic conditions. We believe that the findings presented here are unique and may be beneficial when treating similar cases. |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 19% |
| India | 2 | 10% |
| China | 1 | 5% |
| Spain | 1 | 5% |
| Canada | 1 | 5% |
| Indonesia | 1 | 5% |
| Egypt | 1 | 5% |
| France | 1 | 5% |
| Venezuela, Bolivarian Republic of | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 8 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 67% |
| Scientists | 4 | 19% |
| Practitioners (doctors, other healthcare professionals) | 3 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 14% |
| Student > Bachelor | 2 | 9% |
| Student > Master | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Other | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 10 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 32% |
| Biochemistry, Genetics and Molecular Biology | 3 | 14% |
| Nursing and Health Professions | 1 | 5% |
| Unknown | 11 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2022.
All research outputs
#2,684,862
of 23,630,563 outputs
Outputs from BMC Nephrology
#237
of 2,542 outputs
Outputs of similar age
#50,346
of 314,355 outputs
Outputs of similar age from BMC Nephrology
#4
of 72 outputs
Altmetric has tracked 23,630,563 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,542 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,355 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.